Colin D Johnson1, Nicola Williamson2, Gwendolyn Janssen-van Solingen3, Rob Arbuckle4, Chloe Johnson4, Sarah Simpson4, Doris Staab5, Enrique Dominguez-Munoz6, Phillippe Levy7, Gary Connett8, Markus M Lerch9. 1. University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom. 2. Adelphi Values, Cheshire, England, United Kingdom. Electronic address: nicola.williamson@adelphivalues.com. 3. Abbott Product Operations AG, EPD HQ, Allschwil, Switzerland. 4. Adelphi Values, Cheshire, England, United Kingdom. 5. Charité University Hospital, Berlin, Germany. 6. University Hospital of Santiago de Compostela, Santiago de Compostela, Spain. 7. Université Denis Diderot-Paris VII Hôpital Beaujon, Clichy Cedex, France. 8. Southampton Children's Hospital, Hampshire, England, United Kingdom. 9. University Medicine Greifswald, Greifswald, Germany.
Abstract
BACKGROUND/ OBJECTIVES: Pancreatic exocrine insufficiency (PEI) is commonly caused by chronic pancreatitis (CP) or cystic fibrosis (CF). There are no PEI-specific patient-reported assessments of symptoms and impacts. The PEI Questionnaire (PEI-Q) was developed through qualitative research with PEI patients and expert clinical input. This study evaluated the psychometric properties of the PEI-Q. METHODS: 162 PEI patients (CF = 71 and CP = 91), 62 diarrhoea-specific irritable bowel syndrome (IBS-D) patients and 60 healthy controls completed the 26-item PEI-Q and the Gastrointestinal Quality of Life Index (GIQLI) at baseline. PEI patients completed the measures again two weeks later to assess the test-retest reliability of the PEI-Q. Analyses supported item reduction and scoring algorithm development, followed by psychometric evaluation. RESULTS: Over 90% of PEI patients completed at least 23 of the 26 items at baseline. Item responses and clinical relevance supported retention of 18 items. Factor analysis supported a three-factor solution (abdominal symptoms, bowel movements, impacts) with adequate model fit. PEI-Q scores had good internal consistency (Cronbach's alpha: 0.77-0.82) and test-retest reliability (ICC: 0.73-0.87). Correlations between PEI-Q and GIQLI supported convergent validity. Known-groups and receiver operating characteristic analyses demonstrated that PEI-Q scores discriminated (p < 0.001) between differing PEI severities, and PEI patients and controls. CONCLUSIONS: The PEI-Q has good validity and reliability. Results indicate that the PEI-Q could be used to aid identification and diagnosis of PEI, assist in the management of patients already diagnosed with PEI, ensuring correct and optimum treatment as well as enhance patient-clinician communication.
BACKGROUND/ OBJECTIVES:Pancreatic exocrine insufficiency (PEI) is commonly caused by chronic pancreatitis (CP) or cystic fibrosis (CF). There are no PEI-specific patient-reported assessments of symptoms and impacts. The PEI Questionnaire (PEI-Q) was developed through qualitative research with PEI patients and expert clinical input. This study evaluated the psychometric properties of the PEI-Q. METHODS: 162 PEI patients (CF = 71 and CP = 91), 62 diarrhoea-specific irritable bowel syndrome (IBS-D) patients and 60 healthy controls completed the 26-item PEI-Q and the Gastrointestinal Quality of Life Index (GIQLI) at baseline. PEI patients completed the measures again two weeks later to assess the test-retest reliability of the PEI-Q. Analyses supported item reduction and scoring algorithm development, followed by psychometric evaluation. RESULTS: Over 90% of PEI patients completed at least 23 of the 26 items at baseline. Item responses and clinical relevance supported retention of 18 items. Factor analysis supported a three-factor solution (abdominal symptoms, bowel movements, impacts) with adequate model fit. PEI-Q scores had good internal consistency (Cronbach's alpha: 0.77-0.82) and test-retest reliability (ICC: 0.73-0.87). Correlations between PEI-Q and GIQLI supported convergent validity. Known-groups and receiver operating characteristic analyses demonstrated that PEI-Q scores discriminated (p < 0.001) between differing PEI severities, and PEI patients and controls. CONCLUSIONS: The PEI-Q has good validity and reliability. Results indicate that the PEI-Q could be used to aid identification and diagnosis of PEI, assist in the management of patients already diagnosed with PEI, ensuring correct and optimum treatment as well as enhance patient-clinician communication.
Authors: Luise Ehlers; Karen Bannert; Sarah Rohde; Peggy Berlin; Johannes Reiner; Mats Wiese; Julia Doller; Markus M Lerch; Ali A Aghdassi; Fatuma Meyer; Luzia Valentini; Ottavia Agrifoglio; Cornelia C Metges; Georg Lamprecht; Robert Jaster Journal: J Cell Mol Med Date: 2020-07-06 Impact factor: 5.310
Authors: Mary E Phillips; Andrew D Hopper; John S Leeds; Keith J Roberts; Laura McGeeney; Sinead N Duggan; Rajesh Kumar Journal: BMJ Open Gastroenterol Date: 2021-06
Authors: Regina Müller; Ali A Aghdassi; Judith Kruse; Markus M Lerch; Peter Simon; Sabine Salloch Journal: Eur J Hum Genet Date: 2020-08-12 Impact factor: 4.246